Neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy for mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer (PICC-2): an open-label, multicentre, randomised, phase 2 trial.
Adding a common arthritis drug to immunotherapy doubles complete tumor response rates in a specific type of advanced colorectal cancer.
This multicenter open-label randomized phase 2 trial (PICC-2) demonstrated that combining the COX-2 inhibitor celecoxib with toripalimab immunotherapy yielded superior pathologic complete response rates compared to toripalimab alone in dMMR/MSI-H locally advanced colorectal cancer. The findings support COX-2 inhibition as a cost-accessible immune sensitizer in biomarker-selected CRC.
What the study was
- Study design
- Randomized Phase 2 Trial
- Population
- dMMR/MSI-H locally advanced colorectal cancer patients
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- The Lancet. Oncology
Why it surfaced
Lancet Oncol RCT in MSI-H/dMMR CRC; celecoxib as immune sensitizer is novel and inexpensive; multicentre design; directly practice-informing for this genomically defined population.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.